Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

Table 3 Key studies of TNF-blocker therapy in ankylosing spondylitis

Outcomes reported
Therapy	Published study	Primary outcome	Radiologic outcome	Follow-up	BASDAI	BASFI	BASMI	QoL	EMS	Fatigue	CRP/ ESR
Infliximab	Braun and colleagues [96–100]	50% improvement in BASDAI at week 12	mSASSS	5 years	x	x	x	x	x		x
Infliximab	Marzo-Ortega and colleagues [101]	Change in BASDAI at weeks 4, 10, 30	MRI inflammatory lesions	30 weeks	x	x		x	x		x
Infliximab	van der Heijde and colleagues [83, 102]	ASAS 20 at week 24	mSASSS	8 years	x	x	x	x	x	x	x
Etanercept	Davis and colleagues [103–105], van der Heijde and colleagues [84]	ASAS 20 at week 12	mSASSS	16 years	x	x	x		x		x
Etanercept	Calin and colleagues [106], Dijkmans and colleagues [107]	ASAS 20 at week 12	mSASSS	8 years	x	x	x		x		x
Adalimumab	van der Heijde and colleagues [108]	ASAS 20 at week 12	NA	24 weeks	x	x	x	x	x		x
Golimumab	Inman and colleagues [109]	ASAS 20 at week 14	NA	24 weeks	x	x	x	x	x		x

ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate; EMS, early morning stiffness; MRI, magnetic resonance imaging; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NA, not applicable; QoL, quality of life.

ISSN: 1478-6362